Australian Arthramid® Canine Elbow Osteoarthritis Clinical Trial in progress in 2025
Arthramid® is a unique and patented 2.5% iPAAG (intra-articular polyacrylamide hydrogel) offering an innovative, safe intra-articular treatment option for veterinarians. It is used to manage joint pain and lameness in animals, including both early and late stages of osteoarthritis, through its precise therapeutic action on the synovial membrane.
2.5% iPAAG has an established track record of success and safety in alleviating joint pain and improving mobility in horses, dogs and humans, and this treatment is now being assessed formally in Australia for canine use, bringing hope to dogs struggling with osteoarthritis.
A pivotal Arthramid Canine Elbow Arthritis Trial has commenced in Australia within nominated veterinary practices in New South Wales and Queensland, with the aim of adding a canine claim to Arthramid’s existing equine lameness registrations in Australia (APVMA No. 86728) and New Zealand (ACVM No. A11596).
Seeking Dogs with Elbow Arthritis to Join a Clinical Trial on Cutting-Edge OA Treatment, Arthramid®
STUDY AIM
Are you the owner of a dog aged 2 to 12 years diagnosed with elbow arthritis?
You and your dog may be suitable to participate in a clinical trial to evaluate this novel injectable treatment which can enhance their quality of life, and also contribute to important research that may benefit countless other pets in the future.
Dogs enrolled in the study will undergo regular assessments to gauge improvements in comfort, mobility and overall quality of life. Participating dogs will receive all study-related veterinary care, medications and monitoring at no cost.
This blinded, controlled field study will follow enrolled dogs for 12 weeks post-treatment.
KEY ELIGIBILITY CRITERIA
- Dogs of any breed, aged from 2 to 12 years
- Bodyweight between 10 and 50 kg
- History, clinical signs and/or physical exam findings consistent with arthritis in one or both elbows, but not in any other joints
- Dogs otherwise in good health
- Most previous and concurrent medications are permitted, depending on their mode of action
- Evidence of elbow arthritis on radiographic, CT or other suitable imaging (This evaluation can be conducted at commencement of the trial, if not already done prior)
RECRUITMENT
A discussion with your current veterinarian is suggested to evaluate your dog’s suitability for inclusion. With your consent, your vet can share your dog’s last 6 – 12 months of veterinary history to research.anz@conturavet.com and, if assessed as a potential trial recruitment, we can refer on to a participating trial practice.
Participating Trial Practices
Shaded zones on the maps below contain practices which are enrolled to participate in this study
Veterinarians requiring further information, including details of Participating Trial Practices, should contact Dr Edwina Lamkin via email research.anz@conturavet.com.
NOTE: ArthramidVet® is a registered S4 for the treatment of lameness in horses (APVMA No. 86728). Use in non-equine species in Australia is currently extra-label and at the veterinarian’s discretion.
